Adiponectin in Obese Women With T2DN and Effects by RAS Blocker - Full Text View

Sponsored by:	Shanghai Jiao Tong University of Medicine
Information provided by:	Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier:	NCT00561704

Purpose

Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

Condition	Intervention
Obese Type 2 Diabetes Diabetic Nephropathy Glucose Metabolism Angiotensin II Type 1 Receptor Blockers	Drug: losartan

MedlinePlus related topics: Diabetes Diabetic Kidney Problems Obesity

Drug Information available for: Dextrose Losartan Losartan potassium Angiotensin II Angiotensin II, ile(5)-

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Parallel Assignment, Safety/Efficacy Study
Official Title:	Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

Further study details as provided by Shanghai Jiao Tong University School of Medicine:

Primary Outcome Measures:

GFR, HbA1c and the adiponectin concentration. [ Time Frame: 6 month ]

Enrollment:	80
Study Start Date:	April 2007
Study Completion Date:	October 2007

Intervention Details:

losartan, 100mg daily,

Detailed Description:

it would be a prospective cohort study. According to BMI, all the women, aged>30yr, diagnosed type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index( fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg daily, 6 month). during the study, the above mentioned parameters will also be recorded 3 month intervals. Meanwhile, any side effects would be pay attention.

Eligibility

Ages Eligible for Study:	30 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Type 2 diabetic nephropathy
CKD at stage 1~4

Exclusion Criteria:

Type 1 diabetes or nondiabetic renal disease
An elevated plasma K level.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00561704

Sponsors and Collaborators

Shanghai Jiao Tong University of Medicine

Investigators

Principal Investigator:

hui min Jin, MD

shanghai No 3 people's hospital

More Information

Study ID Numbers:	ADL
Study First Received:	November 20, 2007
Last Updated:	November 20, 2007
ClinicalTrials.gov Identifier:	NCT00561704
Health Authority:	China: State Food and Drug Administration

Keywords provided by Shanghai Jiao Tong University School of Medicine:

obese female
Type 2 Diabetes
Diabetic Nephropathy

Glucose Metabolism
Angiotensin II Type 1 Receptor Blockers
Adiponectin

Study placed in the following topic categories:

Obesity
Losartan
Diabetic Nephropathies
Metabolic Diseases
Diabetes Mellitus
Endocrine System Diseases
Angiotensin II

Urologic Diseases
Diabetes Mellitus, Type 2
Kidney Diseases
Endocrinopathy
Glucose Metabolism Disorders
Metabolic disorder
Diabetes Complications

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Cardiovascular Agents

Anti-Arrhythmia Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009